Literature DB >> 32213625

Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells.

Dinali Wijewarnasuriya1,2, Christina Bebernitz1,2, Andrea V Lopez2, Sarwish Rafiq3, Renier J Brentjens4,5,6.   

Abstract

Although clinical responses with CD19-targeting chimeric antigen receptor (CAR) T-cell treatment have been observed in patients with certain hematologic malignancies, high rates of disease relapse highlight the necessity to understand and improve mechanisms of CAR T-cell failure. Because T-cell dysfunction is thought to contribute to CAR T-cell treatment failure, understanding what mechanisms drive T cells into this dysfunctional state may aid optimal design of efficacious CAR T cells. Dysfunctional CAR T cells have been characterized as having upregulated inhibitory receptors and decreased cytolytic capabilities. Previous studies have identified a role for sustained CAR CD3ζ signaling in CAR T-cell dysfunction. Here, we demonstrate a mechanism that drives dysfunction in CAR T cells through excessive costimulation. Fully activated CD19-targeted CAR T cells were rendered dysfunctional upon stimulation with both endogenous CD28 stimulation and CAR-mediated CD28 costimulation. Costimulation-driven dysfunction of CAR T cells was demonstrated in a syngeneic immunocompetent mouse model, in which CAR T cells were activated with signals 1 (CD3ζ), 2 (CD28), and 3 (IL12). Thus, we show that CAR T-cell dysfunction can be driven through excessive CD28 and 4-1BB costimulation.See related article by Drakes et al., p. 743. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32213625      PMCID: PMC7269815          DOI: 10.1158/2326-6066.CIR-19-0908

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  43 in total

1.  Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.

Authors:  Ravit Oren; Moran Hod-Marco; Maya Haus-Cohen; Sharyn Thomas; Dan Blat; Nerri Duvshani; Galit Denkberg; Yael Elbaz; Fabrice Benchetrit; Zelig Eshhar; Hans Stauss; Yoram Reiter
Journal:  J Immunol       Date:  2014-10-31       Impact factor: 5.422

2.  Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection.

Authors:  Hyun-Tak Jin; Ana C Anderson; Wendy G Tan; Erin E West; Sang-Jun Ha; Koichi Araki; Gordon J Freeman; Vijay K Kuchroo; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

3.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

4.  Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.

Authors:  Mark B Geyer; Isabelle Rivière; Brigitte Sénéchal; Xiuyan Wang; Yongzeng Wang; Terence J Purdon; Meier Hsu; Sean M Devlin; Elizabeth Halton; Nicole Lamanna; Jurgen Rademaker; Michel Sadelain; Renier J Brentjens; Jae H Park
Journal:  Mol Ther       Date:  2018-06-15       Impact factor: 11.454

5.  Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains.

Authors:  Cristina R Ferrone; Miguel-Angel Perales; Stacie M Goldberg; C Joy Somberg; Daniel Hirschhorn-Cymerman; Polly D Gregor; Mary Jo Turk; Teresa Ramirez-Montagut; Jason S Gold; Alan N Houghton; Jedd D Wolchok
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

6.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Authors:  Hollie J Pegram; James C Lee; Erik G Hayman; Gavin H Imperato; Thomas F Tedder; Michel Sadelain; Renier J Brentjens
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

7.  Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.

Authors:  James N Kochenderfer; Zhiya Yu; Dorina Frasheri; Nicholas P Restifo; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-14       Impact factor: 22.113

8.  Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.

Authors:  Andrea Schietinger; Mary Philip; Varintra E Krisnawan; Edison Y Chiu; Jeffrey J Delrow; Ryan S Basom; Peter Lauer; Dirk G Brockstedt; Sue E Knoblaugh; Günter J Hämmerling; Todd D Schell; Natalio Garbi; Philip D Greenberg
Journal:  Immunity       Date:  2016-08-09       Impact factor: 31.745

9.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

Authors:  Renier J Brentjens; Jean-Baptiste Latouche; Elmer Santos; Francesc Marti; Michael C Gong; Clay Lyddane; Philip D King; Steven Larson; Mark Weiss; Isabelle Rivière; Michel Sadelain
Journal:  Nat Med       Date:  2003-02-10       Impact factor: 53.440

10.  Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.

Authors:  Christian Münz; Ulf Petrausch; Pratiksha Gulati; Julia Rühl; Abhilash Kannan; Magdalena Pircher; Petra Schuberth; Katarzyna J Nytko; Martin Pruschy; Simon Sulser; Mark Haefner; Shawn Jensen; Alex Soltermann; Wolfgang Jungraithmayr; Maya Eisenring; Thomas Winder; Panagiotis Samaras; Annett Tabor; Rene Stenger; Roger Stupp; Walter Weder; Christoph Renner
Journal:  Clin Cancer Res       Date:  2018-05-10       Impact factor: 12.531

View more
  7 in total

1.  CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function.

Authors:  Justin C Boucher; Gongbo Li; Hiroshi Kotani; Maria L Cabral; Dylan Morrissey; Sae Bom Lee; Kristen Spitler; Nolan J Beatty; Estelle V Cervantes; Bishwas Shrestha; Bin Yu; Aslamuzzaman Kazi; Xuefeng Wang; Said M Sebti; Marco L Davila
Journal:  Cancer Immunol Res       Date:  2020-11-13       Impact factor: 12.020

2.  Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist.

Authors:  Punit Upadhyaya; Johanna Lahdenranta; Kristen Hurov; Sailaja Battula; Rachel Dods; Eric Haines; Marianna Kleyman; Julia Kristensson; Jessica Kublin; Rachid Lani; Jun Ma; Gemma Mudd; Elizabeth Repash; Katerine Van Rietschoten; Tom Stephen; Fanglei You; Helen Harrison; Liuhong Chen; Kevin McDonnell; Philip Brandish; Nicholas Keen
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

Review 3.  Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy.

Authors:  Hyunmin Chung; Haiyoung Jung; Ji-Yoon Noh
Journal:  Int J Mol Sci       Date:  2021-11-09       Impact factor: 5.923

4.  4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.

Authors:  Emiliano Roselli; Justin C Boucher; Gongbo Li; Hiroshi Kotani; Kristen Spitler; Kayla Reid; Estelle V Cervantes; Yannick Bulliard; Nhan Tu; Sae Bom Lee; Bin Yu; Frederick L Locke; Marco L Davila
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751

Review 5.  Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers.

Authors:  Aaron J Harrison; Xin Du; Bianca von Scheidt; Michael H Kershaw; Clare Y Slaney
Journal:  Immunother Adv       Date:  2021-07-31

Review 6.  Co-Stimulatory Receptor Signaling in CAR-T Cells.

Authors:  Mackenzie M Honikel; Scott H Olejniczak
Journal:  Biomolecules       Date:  2022-09-15

7.  Speed and Location Both Matter: Antigen Stimulus Dynamics Controls CAR-T Cell Response.

Authors:  Can Liu; Timothy Qi; J Justin Milner; Yong Lu; Yanguang Cao
Journal:  Front Immunol       Date:  2021-10-08       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.